RxDoctor Payments Data

Jennifer Hayes, PA

Physician Assistant · Grand Forks, NDNPI 1548812704

Payments from drug & device makers

$858in general payments, 2019–2025

Across 12 payments — averaging $71.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$179
  • AstraZeneca$167
  • Lilly USA, LLC$163
  • Novo Nordisk$148
  • Medtronic$81
  • Exact Sciences$72
  • plus $49 from 2 others

What the payments were for

  • Food & beverage$858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$858 in reported general payments places this provider in the 80th percentile of 355 physician assistant providers in North Dakota.

See all physician assistant providers in North Dakota

Medicare billing

Part B allowed, 2024
$73,721
Medicare patients
359
Services billed
881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$79,786
JardianceEmpagliflozin79$73,364
OzempicSemaglutide62$69,477
XareltoRivaroxaban18$21,562
MounjaroTirzepatide19$19,900
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$15,491
Fiasp FlextouchInsulin Aspart (Niacinamide)13$14,299
Tresiba Flextouch U-200Insulin Degludec13$9,603
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$7,959
Janumet XrSitagliptin Phos/Metformin Hcl11$6,343
Potassium Chloride87$6,018
Atorvastatin Calcium385$4,671
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,427
Levothyroxine Sodium276$3,324
Arnuity ElliptaFluticasone Furoate11$2,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$148$69,47762 claims
Lilly USA, LLCMounjaro$163$19,90019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 355 physician assistant providers in North Dakota.

Other physician assistant in Grand Forks

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →